Examining 192 ads in 12 journals, researchers found that 58 percent didn’t calculate serious risks of the drugs, including death, while 48 percent didn’t have references that could be confirmed and almost 29 percent couldn’t adequately quantify effectiveness.
Researchers recommended the FDA create more objective advertisement guidelines requiring transparent presentation of basic safety and efficacy information.
Related Articles on Pharmaceuticals:
Amerinet, Sandoz Sign Agreement for Pharmaceutical Products
6 Things to Know About Pharmaceuticals and Outsourcing Pharmaceutical Solutions
Pfizer Reports “Potentially Improper Payments” Made Outside U.S.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
